This is going to be an evolving story of a Disabled Female chronic pain pt

Pt’s statements in RED: My words are in Green

Remember she is doing speech to text

This disabled female pt reached out to me Aug 4th and her doc had just abruptly cut her oral opioids she had been taking for ~ 10yr from 90 MME/day to 30 MME/day and put a Buprenorphine patch on her the next day. This is just starting to evolve but I am going to leave this post at the top of the first page and update as things happen – STAY TUNE

This is Aug 5th:

My. Primary. Just upped my blood. Pressure meds he said. It could ending up having. A stroke    Could it be the patch. Causing my blood. Pressure. Going. Up. So. High

Is your doctor just an employee of a large hospital system. I would like to put a spot light on his employer – let me know

 

 

 

A day or two after she put the buprenorphine patch on she was scheduled to have a treadmill cardiac stress test. Before the test, they took her blood pressure and it was 240/120 – what the American heart Association claims is a hypertensive crisis level. This test was done in part of a hospital system. Of course the stress test was cancelled, and the staff just SENT HER HOME. Before she had the patch on, her blood pressure was more normalish. Here is the American Heart Association on its definition of blood pressure. You may have to click on the graphic TWICE to make it enlarge and more readable

 

9 Responses

  1. Why is there all these ways to switch people to bupe in the 1st place when they were doing absolutely fine on whatever they were already taking? From all I’ve seen and heard, it doesn’t work at all or even close to other full agonist opioids so why the change?

    • IMO, the prescribers believe that it is a “safe harbor” until the DEA finds out that the pts getting bupe are going out on the street and exchanging it for the drug they want. Apparently believing that it is safer prescribing a C-III, BUT they forget that prescribing a Benzo a C-IV IS NOT SAFE!

  2. Buprenorphine seems to be getting a bad rap when it comes to chronic pain patients. I agree that the oral film you put in on the inside of your mouth is bad and should be pulled from market. My question…does the patch, when used specifically for pain , do anything for chronic pain. Especially when there are different levels of chronic pain. Some patients may have severe chronic pain like can’t get out of bed pain. Or some patients have moderate or mild chronic pain that is irritating but they can function in most settings such as go to work, do grocery shopping. Thanks for letting me reply…

  3. 90mme to 30mme. That’s below most documentation I’ve seen mandating specific levels. I believe that 50mme was the bottom that the updated 2022 CDC Guidelines and CARA 2016 promoted. Regardless, that’s not in anyway condoning this draconian reduction and I thank you for sharing her story.

    • I really feel sorry for this lady. I can’t believe how fast they dropped her dosage, and with no warning. It’s not supposed to be more than a 10% change per week, or longer if needed. Doctors can write for 90 mme if they feel it’s appropriate, have plenty of documentation, and it’s in the normal course of their duties, thanks to the SCOTUS ruling in Ruan v United States. I hope if she went to the ER, they referred her to a good pain doctor, because it honestly sounds like the buprenorphine patches are causing some sort of cardiac issues. If a cardiologist won’t do a stress test on you because your BP is too high, that’s bad! I hope things get straightened out for her! ❤️‍

      • Why was she lowered or changed to different med when she was stable already?

        • educated guess— the DEA had told him directly and/or he attended some meeting where the DEA made a presentation – if you don’t want to lose your license …you will put all your pts on Buprenorphine patches. IMO, in this particular case with this woman, this doctor did not even come close to the standard of care and best practices. To wean a pt down on Oxycodone and transition a pt to buprenorphine.
          Transitioning a patient from 90 MME/day oxycodone to buprenorphine requires careful adherence to evidence-based protocols and a clear understanding of the pharmacology involved. The best practices emphasize patient safety, minimizing withdrawal and avoiding precipitated withdrawal.
          Standard of Care

          The traditional STOP-START induction involves discontinuing full opioid agonists (like oxycodone) for 12-24 hours, waiting for the onset of mild to moderate withdrawal symptoms, and then starting buprenorphine (typically sublingual, mg-strength) dosing.

          Recent best practices for high-dose opioid transitions (>90 MME) recommend close monitoring and may use initial buprenorphine dosing strategies of titration after withdrawal symptoms appear, with frequent clinical reassessment.

          An alternative, low-dose or microdosing (Bernese method), initiates buprenorphine (often mcg or very low mg doses) while the patient continues the full opioid agonist, slowly increasing buprenorphine and tapering the other opioid, to minimize risk of precipitated withdrawal and manage discomfort.
          Best Practice Recommendations

          Assess stability and risks: Identify opioid use disorder (OUD), other behavioral risks, and patient stability. Monitor closely during transition, as high-dose chronic opioid patients may stabilize on lower buprenorphine doses than those with OUD.

          Patient preference: Involve the patient’s preferences in selecting between traditional withdrawal-based and low-dose/microinduction techniques.

          Formulation selection: For 90 MME/day, typically sublingual buprenorphine (mg dosing) or buccal film (mcg dosing) is used; patch is less preferred at higher doses.

          Naloxone co-prescription: Always provide naloxone and education about overdose risk during and after transition, especially if reverting to full agonists.

          Adjuvant support: Continue non-opioid analgesics and comfort measures to manage withdrawal symptoms when needed.
          Protocol Overview

          STOP-START (traditional): Discontinue oxycodone, wait 12-24 hours for mild-moderate withdrawal, then start 2-4 mg buprenorphine SL, titrate upward.

          Low-dose/microdosing: Begin 0.2-0.5 mg buprenorphine SL or buccal mcg doses while maintaining opioid, gradually titrate buprenorphine up and other opioid down over 3-7 days.

          These protocols can vary by formulation, clinical scenario, and institutional guidelines. Frequent reassessment and patient-centered modifications are critical for safety and efficacy.

          References

          For detailed tables and sample conversion schedules, see the VA guidelines and recent review articles.

          This approach closely follows current standards and published guidelines for converting from high-dose oxycodone to buprenorphine, prioritizing withdrawal mitigation and patient function.

  4. Dr. Steve, That ought to be a very interesting case! I’m looking forward to reading about it with my coffee to see how it unfolds and what happened to the poor lady

Leave a Reply to PharmaciststeveCancel reply

Discover more from PHARMACIST STEVE

Subscribe now to keep reading and get access to the full archive.

Continue reading